EDMONTON, Alberta, July 9, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) (“Isotechnika”) announced today that Lux Biosciences, Inc. (“Lux”) has completed patient enrollment in its Phase 3 clinical study using voclosporin (branded as Luveniq™ by Lux) for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability. Lux anticipates that data from the Phase 3 study will be available early in the first quarter of 2013.
